Study Stopped
The reasons for stopping the research are : * Inclusion difficulties (demanding inclusion and exclusion criteria), * The Covid-19 pandemic
Miniinvasive Corneal Neurotization. A Pilot Study.
MICORNE
1 other identifier
interventional
1
1 country
1
Brief Summary
Neurotrophic keratitis (NK) is a degenerative disease of the cornea due to the impairment of the nasociliary branch of the ophthalmic nerve. Reduced corneal sensation lead to several corneal lesions including spontaneous ulcerations, delayed wound healing, corneal scarring, neovascularization, thinning, perforation or infection. An important and permanent visual loss of is frequently associated with the condition. NK can be congenital or acquired. Its acquired forms can be due to traumatic, infectious (herpes, zoster), neoplastic or iatrogenic causes. There is currently no specific medical treatment. Surgical reconstruction techniques of sensory neurotizations have recently been described in young patients suffering traumatic, congenital or neoplastic NK using supratrochlear nerves as the sensory donor nerves and sural nerve as healthy graft. A neurotization involves the transfer of a healthy donor nerve segment into a tissue to reestablish either motor or sensory innervation. The aim of the present study is to assess the outcomes of a novel sensory neurotization technique for the treatment of severe NK in adult patients (Stages 2 and 3 of Mackie classification). Corneal neurotizations will be performed using either ipsilateral supraorbital nerve as donor nerve (direct neurotization) or contralateral supraorbital nerve as donor nerve and a segment of the lateral antebrachial cutaneous nerve as graft. Small-size skin incisions (less than 3 centimeters) will be made in one or both eyebrow and an endoscopic device will help the surgeons to localize and dissect the supraorbital nerve. Donor nerves or graft will be sutured to the neurotrophic corneas. Adult patients with unilateral NK due to infectious, traumatic or iatrogenic causes will be included.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Jun 2017
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
January 17, 2017
CompletedFirst Posted
Study publicly available on registry
January 31, 2017
CompletedStudy Start
First participant enrolled
June 1, 2017
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 22, 2019
CompletedStudy Completion
Last participant's last visit for all outcomes
January 22, 2019
CompletedSeptember 20, 2021
September 1, 2021
1.6 years
January 17, 2017
September 13, 2021
Conditions
Outcome Measures
Primary Outcomes (1)
Corneal sensation scores.
12 months
Study Arms (1)
Miniinvasive corneal neurotization
OTHERInterventions
Neurotization of a neurotrophic cornea
Eligibility Criteria
You may qualify if:
- Patient older than 18.
- NK stages 2 and 3 (Mackie's classification).
- Non-response to maximal medical treatment (lachrymal substitution, autologous serum).
- Postherpetic or post-zoster NK (Group 1).
- Postoperative NK (neurosurgery and trigeminal thermocoagulation) (Group 2).
- Posttraumatic NK (orbital trauma, ocular burn) (Group 3).
- No ocular hypertony in both eyes.
- Visual acuity \> 20/40 on the contralateral eye.
- Written consent of the patient.
- Patient benefiting from national health coverage (either as a direct user or beneficiary).
You may not qualify if:
- Impossibility of general anesthesia.
- Herpetic or zoster recurrence in the 6 months prior surgery.
- Length of NK evolution \> 5 years.
- Congenital NK.
- Bilateral NK.
- Other causes of NK: diabeta mellitus, amylosis, sarcoidosis, multiple sclerosis, vitamin A or B12 deficiency, Sjögren syndrome, GVH disease, topical NSAID, topical beta-blockers, history of refractive surgery.
- Mental illness.
- Adult with legal guardian or guardianship.
- Pregnancy.
- Breast-feeding.
- Patient's unable to understand informations.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Les Hôpitaux Universitaires
Strasbourg, 67000, France
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
January 17, 2017
First Posted
January 31, 2017
Study Start
June 1, 2017
Primary Completion
January 22, 2019
Study Completion
January 22, 2019
Last Updated
September 20, 2021
Record last verified: 2021-09
Data Sharing
- IPD Sharing
- Will not share